321 related articles for article (PubMed ID: 16052302)
1. Effects of SolCD39, a novel inhibitor of Platelet Aggregation, on Platelet Deposition and Aggregation after PTCA in a Porcine Model.
Buergler JM; Maliszewski CR; Broekman MJ; Kaluza GL; Schulz DG; Marcus AJ; Raizner AE; Kleiman NS; Ali NM
J Thromb Thrombolysis; 2005 Apr; 19(2):115-22. PubMed ID: 16052302
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of platelet recruitment by endothelial cell CD39/ecto-ADPase: significance for occlusive vascular diseases.
Marcus AJ; Broekman MJ; Drosopoulos JH; Pinsky DJ; Islam N; Maliszewsk CR
Ital Heart J; 2001 Nov; 2(11):824-30. PubMed ID: 11770867
[TBL] [Abstract][Full Text] [Related]
3. Role of extracellular ATP metabolism in regulation of platelet reactivity.
Birk AV; Broekman MJ; Gladek EM; Robertson HD; Drosopoulos JH; Marcus AJ; Szeto HH
J Lab Clin Med; 2002 Sep; 140(3):166-75. PubMed ID: 12271274
[TBL] [Abstract][Full Text] [Related]
4. Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: implications for ischemic vascular diseases.
Marcus AJ; Broekman MJ; Drosopoulos JH; Islam N; Pinsky DJ; Sesti C; Levi R
J Pharmacol Exp Ther; 2003 Apr; 305(1):9-16. PubMed ID: 12649347
[TBL] [Abstract][Full Text] [Related]
5. Human solCD39 inhibits injury-induced development of neointimal hyperplasia.
Drosopoulos JH; Kraemer R; Shen H; Upmacis RK; Marcus AJ; Musi E
Thromb Haemost; 2010 Feb; 103(2):426-34. PubMed ID: 20024507
[TBL] [Abstract][Full Text] [Related]
6. Site-directed mutagenesis of human endothelial cell ecto-ADPase/soluble CD39: requirement of glutamate 174 and serine 218 for enzyme activity and inhibition of platelet recruitment.
Drosopoulos JH; Broekman MJ; Islam N; Maliszewski CR; Gayle RB; Marcus AJ
Biochemistry; 2000 Jun; 39(23):6936-43. PubMed ID: 10841775
[TBL] [Abstract][Full Text] [Related]
7. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100).
Kottke-Marchant K; Powers JB; Brooks L; Kundu S; Christie DJ
Clin Appl Thromb Hemost; 1999 Apr; 5(2):122-30. PubMed ID: 10725993
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effect of SolCD39, a novel platelet aggregation inhibitor, on transient middle cerebral artery occlusion in rats.
Belayev L; Khoutorova L; Deisher TA; Belayev A; Busto R; Zhang Y; Zhao W; Ginsberg MD
Stroke; 2003 Mar; 34(3):758-63. PubMed ID: 12624304
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39.
Gayle RB; Maliszewski CR; Gimpel SD; Schoenborn MA; Caspary RG; Richards C; Brasel K; Price V; Drosopoulos JH; Islam N; Alyonycheva TN; Broekman MJ; Marcus AJ
J Clin Invest; 1998 May; 101(9):1851-9. PubMed ID: 9576748
[TBL] [Abstract][Full Text] [Related]
10. ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions.
Degen H; Borst O; Ziegler M; Mojica Munoz AK; Jamasbi J; Walker B; Göbel S; Fassbender J; Adler K; Brandl R; Münch G; Lorenz R; Siess W; Gawaz M; Ungerer M
J Am Heart Assoc; 2017 Jul; 6(8):. PubMed ID: 28751543
[TBL] [Abstract][Full Text] [Related]
11. Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection.
Marcus AJ; Broekman MJ; Drosopoulos JH; Olson KE; Islam N; Pinsky DJ; Levi R
Semin Thromb Hemost; 2005 Apr; 31(2):234-46. PubMed ID: 15852226
[TBL] [Abstract][Full Text] [Related]
12. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
[TBL] [Abstract][Full Text] [Related]
13. Association between the efficacy of dual antiplatelet therapy and the development of in-stent neointimal hyperplasia in porcine coronary arteries.
Hemetsberger R; Farhan S; Strehblow C; Sperker W; Pavo I; Petrasi Z; Hemetsberger H; Posa A; Huber K; Glogar D; Gyöngyösi M
Coron Artery Dis; 2008 Dec; 19(8):635-43. PubMed ID: 19005299
[TBL] [Abstract][Full Text] [Related]
14. Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions.
Kleiman NS; Grazeiadei N; Maresh K; Taylor RJ; Frederick B; Lance ET; Effron MB; Jordan RE; Mascelli MA
Am Heart J; 2000 Sep; 140(3):492-501. PubMed ID: 10966553
[TBL] [Abstract][Full Text] [Related]
15. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39.
Marcus AJ; Broekman MJ; Drosopoulos JH; Islam N; Alyonycheva TN; Safier LB; Hajjar KA; Posnett DN; Schoenborn MA; Schooley KA; Gayle RB; Maliszewski CR
J Clin Invest; 1997 Mar; 99(6):1351-60. PubMed ID: 9077545
[TBL] [Abstract][Full Text] [Related]
16. Soluble saccharides block the inhibition of agonist-induced human platelet aggregation observed after in vitro incubation of human platelet-rich plasma with porcine aortic endothelial cells.
Magnusson S; Romano EL; Hallberg E; Wadenvik H; Breimer ME
Transpl Int; 1998; 11(5):345-52. PubMed ID: 9787410
[TBL] [Abstract][Full Text] [Related]
17. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries.
Yao SK; Ober JC; McNatt J; Benedict CR; Rosolowsky M; Anderson HV; Cui K; Maffrand JP; Campbell WB; Buja LM
Circ Res; 1992 Jan; 70(1):39-48. PubMed ID: 1727687
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel strategy to target CD39 antithrombotic activity to the endothelial-platelet microenvironment in kidney ischemia-reperfusion injury.
Sashindranath M; Dwyer KM; Dezfouli S; Selan C; Crikis S; Lu B; Yuan Y; Hickey MJ; Peter K; Robson SC; Cowan PJ; Nandurkar HH
Purinergic Signal; 2017 Jun; 13(2):259-265. PubMed ID: 28343356
[TBL] [Abstract][Full Text] [Related]
19. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
[TBL] [Abstract][Full Text] [Related]
20. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain.
Pinsky DJ; Broekman MJ; Peschon JJ; Stocking KL; Fujita T; Ramasamy R; Connolly ES; Huang J; Kiss S; Zhang Y; Choudhri TF; McTaggart RA; Liao H; Drosopoulos JH; Price VL; Marcus AJ; Maliszewski CR
J Clin Invest; 2002 Apr; 109(8):1031-40. PubMed ID: 11956240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
